Capsule Summary Slidesets

Share

Program Content

Activities

  • PhaseED-Seq MRD in DLBCL
    Pooled Analysis of PhaseED-Seq MRD-Negativity Assessment as Surrogate Endpoint After Frontline Induction Therapy in Patients With DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2022

    Expires: December 12, 2023

    View Activity
  • CAPTIVATE MRD Cohort
    CAPTIVATE: 5-Yr Follow-up of Continued Ibrutinib vs Placebo in Patients With CLL/SLL and Undetectable MRD After First-line Ibrutinib + Venetoclax
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2022

    Expires: December 13, 2023

    View Activity
  • TRIANGLE
    TRIANGLE: Phase III Trial of Ibrutinib + CIT With or Without ASCT vs CIT Followed by ASCT in Younger Patients With Previously Untreated MCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

    View Activity
  • AVO in High-Risk CLL
    Phase II Trial: Updated Results of Frontline Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Untreated High-Risk CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

    View Activity
  • Acalabrutinib/LenR in MCL
    Acalabrutinib + Lenalidomide and Rituximab With MRD Monitoring in Previously Untreated Mantle Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

    View Activity
  • BV + AVD in Unfavorable-Risk cHL
    Extended Follow-up Results From a Pilot Study of Brentuximab Vedotin + AVD in Newly Diagnosed, Early-Stage, Unfavorable-Risk cHL Using Baseline MTV and PET2 Evaluation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

    View Activity
  • AN + AD for cHL
    Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine as Frontline Combination Therapy for Advanced-Stage cHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • SYMPHONY-1: Phase Ib Results
    SYMPHONY-1: Phase Ib Results of Tazemetostat + Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • Phase I/II EPCORE NHL-2
    Phase I/II EPCORE NHL-2 Trial Update: Epcoritamab + Rituximab/Lenalidomide in Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • MATRix/IELSG43
    MATRix/IELSG43: Phase III Trial of High-Dose Chemotherapy + ASCT vs Nonmyeloablative Chemoimmunotherapy as Consolidation for Primary CNS Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • ALPINE: Final Analysis
    ALPINE: Final Analysis of Zanubrutinib vs Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2022

    Expires: December 18, 2023

    View Activity

Provided by

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen